Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 1,296

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial

Open access
Shitara, Kohei, Özgüroğlu, Mustafa, Bang, Yung-Jue, Di Bartolomeo, Maria, Mandalà, Mario, Ryu, Min-Hee, Fornaro, Lorenzo, Olesiński, Tomasz, Caglevic, Christian, Chung, Hyun C, Muro, Kei, Goekkurt, Eray, Mansoor, Wasat, McDermott, Raymond S, Shacham-Shmueli, Einat, Chen, Xinqun, Mayo, Carlos, Kang, S Peter, Ohtsu, Atsushi, Fuchs, Charles S, Lerzo, Guillermo, O'Connor, Juan Manuel, Mendez, Guillermo Ariel, Lynam, James, Tebbutt, Niall, Wong, Mark, Strickland, Andrew, Karapetis, Chris, Goldstein, David, Vasey, Paul, Van Laethem, Jean-Luc, Van Cutsem, Eric, Berry, Scott, Vincent, Mark, Muller, Bettina, Rey, Felipe, Zambrano, Angela, Guerra, Joaquin, Krogh, Merete, Baeksgaard, Lene, Yilmaz, Mette, Elme, Anneli, Magi, Andrus, Auvinen, Paivi, Alanko, Tuomo, Moehler, Markus, Kunzmann, Volker, Seufferlein, Thomas, Thuss-Patience, Peter, Goekkurt, Eray, Hoehler, Thomas, Haag, Georg, Al-Batran, Salah-Eddin, Castro, Hugo, Lopez, Karla, Aguilar Vasquez, Mynor, Sandoval, Mario, Lam, Ka On, Cuffe, Sinead, Kelly, Cathy, Geva, Ravit, Shacham-Shmueli, Einat, Hubert, Ayala, Beny, Alex, Brenner, Baruch, Giuseppe, Aprile, Falcone, Alfredo, Maiello, Evaristo, Passalacqua, Rodolfo, Montesarchio, Vincenzo, Hara, Hiroki, Chin, Keisho, Nishina, Tomohiro, Komatsu, Yoshito, Machida, Nozumo, Hironaka, Shuichi, Satoh, Taroh, Tamura, Takao, Sugimoto, Naotaoshi, Cho, Haruhiko, Omuro, Yashushi, Kato, Ken, Goto, Masahiro, Hyodo, Ichinosuke, Yoshida, Kazuhiro, Baba, Hideo, Esaki, Taito, Furuse, Junji, Wan Mohammed, Wan Zamaniah, Hernandez Hernandez, Carlos, Casas Garcia, Juan, Dominguez Andrade, Adriana, Clarke, Katriona, Hjortland, Geir, Glenjen, Nils, Kubiatowski, Tomasz, Jacek, Jassem, Wojtukiewicz, Marek, Lazarev, Sergey, Lancukhay, Yuri, Afanasayev, Sergey, Moiseyenko, Vladimir, Kostorov, Vladimir, Protsenko, Svetlana, Shirinkin, Vadim, Sakaeva, Dina, Fadeeva, Natalia, Yong, Wei Peng, Ng, Chau Hsien Matthew, Robertson, Barbara, Rapaport, Bernardo, Cohen, Graham, Dreosti, Lydia, Ruff, Paul, Jacobs, Conrad, Landers, Gregory, Szpak, Waldemar, Roh, Sang-Young, Lee, Jeeyun, Kim, Yeul Hong, Bang, Yung-Jue, Chung, Hyun Cheol, Ryu, Min-Hee, Alsina Maqueda, Maria, Longo Munoz, Federico, Cervantes Aguilar, Andres, Aranda Aguilar, Enrique, Garcia Alfonso, Pilar, Rivera, Fernando, Feliu Batle, Jaime, Pazo Cid, Roberto, Yeh, Kun-Huei, Chen, Jen-Shi, Chao, Yee, Yen, Chia-Jui, Özgüroğlu, Mustafa, Kara, Oguz, Yalcin, Suayib, Hochhauser, Daniel, Chau, Ian, Benson, Al, Shankaran, Veena, Shaib, Walid, Philip, Philip, Sharma, Vivek, Siegel, Robert, Sun, Weijing, Wainberg, Zev, George, Ben, Bullock, Andrea, Myrick, Samuel, Faruol, Josephine, Siegel, Richard, Larson, Timothy, Becerra, Carlos, Ratnam, Suresh, Richards, Donald A., Riche, Stephen L.·2018·The Lancet
DOI 10.1016/s0140-6736(18)31257-1
Open this paper in CoChat — free account

Abstract

BACKGROUND Patients with advanced gastric or gastro-oesophageal junction cancer that progresses on chemotherapy have poor outcomes. We compared pembrolizumab with paclitaxel in patients with advanced gastric or gastro-oesophageal junction cancer that progressed on first-line chemotherapy with a platinum and fluoropyrimidine. METHODS This randomised, open-label, phase 3 study was done at 148 medical centres in 30 countries. Eligible patients were randomised (1:1) in blocks of four per stratum with an interactive voice-response and integrated web-response system to receive either pembrolizumab 200 mg every 3 weeks for up to 2 years or standard-dose paclitaxel. Primary endpoints were overall survival and progression-free survival in patients with a programmed cell death ligand 1 (PD-L1) combined positive score (CPS) of 1 or higher. Safety was assessed in all patients, irrespective of CPS. The significance threshold for overall survival was p=0·0135 (one-sided). This trial is registered at ClinicalTrials.gov, number NCT02370498. FINDINGS Between June 4, 2015, and July 26, 2016, 592 patients were enrolled. Of the 395 patients who had a PD-L1 CPS of 1 or higher, 196 patients were assigned to receive pembrolizumab and 199 patients were assigned to receive paclitaxel. As of Oct 26, 2017, 326 patients in the population with CPS of 1 or higher had died (151 [77%] of 196 patients in the pembrolizumab group and 175 [88%] of 199 patients in the paclitaxel group). Median overall survival was 9·1 months (95% CI 6·2-10·7) with pembrolizumab and 8·3 months (7·6-9·0) with paclitaxel (hazard ratio [HR] 0·82, 95% CI 0·66-1·03; one-sided p=0·0421). Median progression-free survival was 1·5 months (95% CI 1·4-2·0) with pembrolizumab and 4·1 months (3·1-4·2) with paclitaxel (HR 1·27, 95% CI 1·03-1·57). In the total population, grade 3-5 treatment-related adverse events occurred in 42 (14%) of the 294 patients treated with pembrolizumab and 96 (35%) of the 276 patients treated with paclitaxel. INTERPRETATION Pembrolizumab did not significantly improve overall survival compared with paclitaxel as second-line therapy for advanced gastric or gastro-oesophageal junction cancer with PD-L1 CPS of 1 or higher. Pembrolizumab had a better safety profile than paclitaxel. Additional trials of pembrolizumab in gastric and gastro-oesophageal cancer are ongoing. FUNDING Merck Sharp & Dohme, a subsidiary of Merck & Co.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(18)31257-1

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 11 references

Cited by

See all 1,296

Metadata

Authors
Shitara, K., Özgüroğlu, M., Bang, Y.-J., Di Bartolomeo, M., Mandalà, M., Ryu, M.-H., Fornaro, L., Olesiński, T., Caglevic, C., Chung, H. C., Muro, K., Goekkurt, E., Mansoor, W., McDermott, R. S., Shacham-Shmueli, E., Chen, X., Mayo, C., Kang, S. P., Ohtsu, A., Fuchs, C. S., Lerzo, G., O'Connor, J. M., Mendez, G. A., Lynam, J., Tebbutt, N., Wong, M., Strickland, A., Karapetis, C., Goldstein, D., Vasey, P., Van Laethem, J.-L., Van Cutsem, E., Berry, S., Vincent, M., Muller, B., Rey, F., Zambrano, A., Guerra, J., Krogh, M., Baeksgaard, L., Yilmaz, M., Elme, A., Magi, A., Auvinen, P., Alanko, T., Moehler, M., Kunzmann, V., Seufferlein, T., Thuss-Patience, P., Goekkurt, E., Hoehler, T., Haag, G., Al-Batran, S.-E., Castro, H., Lopez, K., Aguilar Vasquez, M., Sandoval, M., Lam, K. O., Cuffe, S., Kelly, C., Geva, R., Shacham-Shmueli, E., Hubert, A., Beny, A., Brenner, B., Giuseppe, A., Falcone, A., Maiello, E., Passalacqua, R., Montesarchio, V., Hara, H., Chin, K., Nishina, T., Komatsu, Y., Machida, N., Hironaka, S., Satoh, T., Tamura, T., Sugimoto, N., Cho, H., Omuro, Y., Kato, K., Goto, M., Hyodo, I., Yoshida, K., Baba, H., Esaki, T., Furuse, J., Wan Mohammed, W. Z., Hernandez Hernandez, C., Casas Garcia, J., Dominguez Andrade, A., Clarke, K., Hjortland, G., Glenjen, N., Kubiatowski, T., Jacek, J., Wojtukiewicz, M., Lazarev, S., Lancukhay, Y., Afanasayev, S., Moiseyenko, V., Kostorov, V., Protsenko, S., Shirinkin, V., Sakaeva, D., Fadeeva, N., Yong, W. P., Ng, C. H. M., Robertson, B., Rapaport, B., Cohen, G., Dreosti, L., Ruff, P., Jacobs, C., Landers, G., Szpak, W., Roh, S.-Y., Lee, J., Kim, Y. H., Bang, Y.-J., Chung, H. C., Ryu, M.-H., Alsina Maqueda, M., Longo Munoz, F., Cervantes Aguilar, A., Aranda Aguilar, E., Garcia Alfonso, P., Rivera, F., Feliu Batle, J., Pazo Cid, R., Yeh, K.-H., Chen, J.-S., Chao, Y., Yen, C.-J., Özgüroğlu, M., Kara, O., Yalcin, S., Hochhauser, D., Chau, I., Benson, A., Shankaran, V., Shaib, W., Philip, P., Sharma, V., Siegel, R., Sun, W., Wainberg, Z., George, B., Bullock, A., Myrick, S., Faruol, J., Siegel, R., Larson, T., Becerra, C., Ratnam, S., Richards, D. A., & Riche, S. L.
Venue
The Lancet
Publisher
Elsevier BV
Published
2018-07
Volume
392
Issue
10142
Pages
123-133
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
DOI
10.1016/s0140-6736(18)31257-1
OpenAlex
W2806614796
Cited by
1,296
References
11
FWCI
105.18
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. https://app.cochat.ai/papers/10.1016/s0140-6736(18)31257-1
The paper
Shitara, K., Özgüroğlu, M., Bang, Y.-J., Di Bartolomeo, M., Mandalà, M., Ryu, M.-H., Fornaro, L., Olesiński, T., Caglevic, C., Chung, H. C., Muro, K., Goekkurt, E., Mansoor, W., McDermott, R. S., Shacham-Shmueli, E., Chen, X., Mayo, C., Kang, S. P., Ohtsu, A., . . . Riche, S. L. (2018). Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. The Lancet. https://doi.org/10.1016/s0140-6736(18)31257-1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.